➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
McKinsey
Harvard Business School
AstraZeneca
Boehringer Ingelheim

Last Updated: January 15, 2021

DrugPatentWatch Database Preview

Litigation Details for Shire ViroPharma LLC v. CSL Behring LLC (D. Del. 2017)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Biologic Drugs cited in Shire ViroPharma LLC v. CSL Behring LLC
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for Shire ViroPharma LLC v. CSL Behring LLC (D. Del. 2017)

Date Filed Document No. Description Snippet Link To Document
2019-02-11 140 Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,616,111 ;10,080,788 ;10,105,423 ;…11 April 2017 1:17-cv-00414-MSG 830 Patent Plaintiff District Court, D. Delaware External link to document
2019-04-23 162 Notice of Service Intrinsic Evidence for Identified Terms of U.S. Patent Nos. 10,080,788, 10,105,423, 10,130,690 and 10,201,595 …11 April 2017 1:17-cv-00414-MSG 830 Patent Plaintiff District Court, D. Delaware External link to document
2019-06-13 190 Answer to Complaint First Amended Counterclaims Concerning U.S. Patent Nos. 10,080,788; 10,105,432; 10,130,690; and 10,201,595…11 April 2017 1:17-cv-00414-MSG 830 Patent Plaintiff District Court, D. Delaware External link to document
2019-06-20 201 Redacted Document First Amended Counterclaims Concerning U.S. Patent Nos. 10,080,788; 10,105,432; 10,130,690; and 10,201,595…11 April 2017 1:17-cv-00414-MSG 830 Patent Plaintiff District Court, D. Delaware External link to document
2019-08-05 216 Opinion - Memorandum Opinion that a fourth continuation patent—Patent No. 10,201,595 (the “’595 Patent”)—would issue on February …more claims of Shire’s ’788 Patent, ’423 Patent, ’690 Patent, and ’595 Patent. (Id. ¶¶ 32– 100.) …at least claim 1 of the ’788 Patent, the ’423 Patent, and the ’690 Patent. The PTO then indicated that…¶¶ 14–19.) B. The Patents-in-Suit 1. The ’788 Patent On September 25, 2018…2018, the United States Patent and Trademark Office (“PTO”) issued the ’788 Patent, entitled “C1-INH Compositions External link to document
2019-11-17 237 Opinion - Memorandum Opinion additional patents—U.S. Patent Nos. 10,080,788 (the “’788 patent”), 10,105,423 (the “’423 patent”), 10,130690… . . .” (’788 patent, claim 1; ’595 patent, claim 1; ’423 patent, claim 1, ’690 patent, claim 1.) Notably… least claim 1 of the ’788 patent, the ’423 patent, and the ’690 patent. The PTO then indicated that…multiple patents owned by Plaintiff. Plaintiff originally alleged infringement of U.S. Patent No. 9,616,111…,130690 (the “’690 patent”), and 10,201,595 (the “’595” patent)—which share the same specification as External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
McKesson
Medtronic
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.